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 Abstract 
 Background:  There is no clear consensus as to which patients with Henoch-Schönlein purpura 
nephritis (HSPN) at risk of a poor outcome should be treated and what therapeutic regimen 
should be used.   Methods:  Nine children with heavy proteinuric HSPN received prompt initia-
tion of methylprednisolone pulse therapy (MPT) combined with tonsillectomy in a prospective 
study.  Results:  At presentation, the mean values for the patients’ urine protein excretion (early-
morning urinary protein/creatinine ratio), serum IgA, activity index (AI), and chronicity index (CI) 
were 5.0 8 5.6 g/g Cr, 135.6 8 56.5 mg/dl, 4.0 8 0.7, and 1.7 8 1.3, respectively. At the second 
biopsy, conducted approximately 24 months after initiation of therapy, the patients’ serum al-
bumin had significantly increased (4.4 8 0.2, p ! 0.01), and the serum IgA and AI had signifi-
cantly decreased (88.1 8 30.8 mg/dl, p ! 0.05; 2.0 8 1.2, p ! 0.01, respectively), whereas the CI 
remained unchanged. Proteinuria disappeared within 24 months in all but 1 patient, and hema-
turia disappeared within 38 months in all patients. No patient showed renal impairment or ex-
perienced a recurrence and/or exacerbation of HSP/HSPN.   Conclusions:  Early treatment with 
MPT combined with tonsillectomy is effective in ameliorating the histopathological progres-
sion and improving the clinical course of children with heavy proteinuric HSPN.
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 Introduction 
  Henoch-Schönlein purpura (HSP) is an IgA-mediated immune-complex vasculitis that 
predominantly affects the skin, joints, gastrointestinal tract, and kidneys. HSP nephritis 
(HSPN) is associated with HSP and usually occurs within 1–2 months of the onset of HSP. 
HSPN is estimated to occur in 20–60% of HSP cases, typically in young children. Most chil-
dren with HSPN present only with hematuria and/or low-grade proteinuria and have good 
prospects for recovery. Renal involvement is the major cause of morbidity and mortality in 
patients with HSP. Although the prognosis for most pediatric HSPN is favorable, patients 
with   1  50% crescents, nephrotic syndrome, heavy proteinuria, hypertension, or renal insuf-
ficiency at onset have been reported to be at risk of a poor outcome   [1–7]  . However, because 
of the small number of patients with severe HSPN and the variable severity of HSPN, there 
is no clear consensus as to which patients with HSPN should be treated and what therapeutic 
regimen should be used.
    It has been suggested that HSPN and IgA nephropathy represent a spectrum of clinical 
presentations of similar disorders. Although the pathogenesis of HSP and HSPN is not 
known, increased polymeric IgA (IgA1) production by the mucosal immune system, includ-
ing the tonsils, in response to certain antigens has been hypothesized as a potential mecha-
nism for the development of the disease. Histopathologically, the granular IgA and C3 im-
mune deposits found predominantly in the mesangium are indistinguishable from those 
seen in IgA nephropathy. It has long been speculated that HSPN and IgA nephropathy share 
common pathogenic mechanisms and may represent different ends of a continuous spec-
trum of disease   [8–11]  .
  Severe HSPN and IgA nephropathy in children have been treated with steroids as an ad-
junct to immunosuppressant therapy. Recently, some studies have reported the efficacy of 
tonsillectomy plus methylprednisolone pulse therapy (MPT) in adults and children with IgA 
nephropathy   [12–14]  . However, there are few reports on the efficacy of tonsillectomy com-
bined with MPT for HSPN   [15–17]  . Furthermore, there has been no prospective study of 
tonsillectomy plus MPT in pediatric HSPN. Therefore, to evaluate the efficacy of MPT com-
bined with tonsillectomy for HSPN, which has a similar pathogenesis to IgA nephropathy, 
we selected a similar therapeutic regimen for HSPN in children. 
    In the present study, we prospectively analyzed the clinical and histopathological out-
comes of heavy proteinuric HSPN in children who underwent early treatment with MPT 
combined with tonsillectomy as the initial treatment.
  Patients  and  Methods 
 Patients 
  Between March 2003 and September 2005, we recruited 10 patients who were newly di-
agnosed with HSPN with persistent heavy proteinuria (  1  1 month) and hematuria. Of the 10 
patients, 9 patients and/or their parents provided written informed consent to participate in 
our therapeutic regimen and to undergo renal biopsy before and after treatment at the De-
partment of Pediatrics at the Yamanashi University of Medicine. The study protocol was in 
accordance with the standards followed at our center. HSPN was diagnosed when hematuria/
proteinuria was associated with a characteristic purpuric rash and abdominal/joint pain. 
Among the 9 patients, HSPN occurred during the first episode of HSP in 8 patients and dur-
ing the first relapse of HSP in 1 patient. None of the patients had a history of recurrent or 
habitual tonsillitis. All patients were treated – regardless of the severity of the patients’ his-
topathological findings – and treatment started within 1 month of the first renal biopsy.103
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  D e f i n i t i o n s  
 Hematuria was considered a positive finding if urinary microscopic examination showed 
  6 5 red blood cells per high-power field. Proteinuria was evaluated by an early-morning uri-
nary total protein/creatinine ratio (u-TP/Cr). In many studies, heavy proteinuria is defined 
as a urinary protein excretion of  6 40 mg  m   – 2   h   – 1 . Because it has been reported that u-TP/Cr 
  6 1 g/g Cr is equivalent to  6 40 mg  m   – 2   h   – 1 , we defined heavy proteinuria as u-TP/Cr  6 1 g/g 
Cr in the present study   [18]  . The disappearance of proteinuria was defined as u-TP/Cr   ! 0.2 
g/g Cr   [19]  . Nephrotic syndrome was defined as the presence of heavy proteinuria with hy-
poalbuminemia (serum albumin   !  2.5 g/dl). Hypertension was defined as a systolic or dia-
stolic blood pressure   1  95th percentile for the patient’s age, based on the recommendations 
of the Pediatric Task Force   [20]  .
    HSPN patients were classified into 5 grades according to the initial clinical presen-
tation. A modified Meadow’s classification was used as follows: grade 1, microscopic he-
maturia; grade 2, persistent proteinuria and/or hematuria; grade 3, nephritic syndrome 
(hematuria, decrease in glomerular filtration rate, GFR, oliguria, hypertension, and edema); 
grade 4, nephrotic syndrome (u-TP/Cr   !  1 g/g Cr, hypoalbuminemia with serum albumin 
  ! 2.5 g/dl and/or hyperlipidemia/edema), and grade 5, mixed nephritic-nephrotic syndrome 
 [21,  22] .
    The clinical outcome was also graded according to the modified Meadow’s criteria for 
each patient at the second biopsy and the most recent follow-up: state A, normal: physical 
examination, urine, and renal function normal; state B, minor urinary abnormalities: nor-
mal physical examination with microscopic   8   recurrent macroscopic hematuria and/or 
proteinuria (u-TP/Cr  ! 1.0 g/g Cr); state C, active renal disease: proteinuria (u-TP/Cr  6 1.0 g/g 
Cr)   8   hypertension, and estimated GFR (eGFR)   1  60 ml/min/1.73 m  2   according to the 
Schwartz formula   [23]  ; state D, renal insufficiency: eGFR   !  60 ml/min/1.73 m  2   (including 
dialysis/transplant or death)   [21]  . 
  P a t h o l o g y  
  All patients underwent percutaneous renal biopsy before treatment. The interval be-
tween the onset of HSPN and the renal biopsy was 2.7  8  3.9 months (range, 0.5–13 months). 
To evaluate the treatment, a second renal biopsy was performed on each patient after com-
pletion of therapy. Glomerular changes were graded according to the classification of the 
International Study of Kidney Diseases in Childhood (ISKDC), using the scoring system 
for IgA nephropathy described by Andreoli and Bergstein  [24] . The activity index (AI) was 
determined by grading mesangial cell proliferation on a scale of 0–3 (0 = none, 1 = mild, 
2 = moderate, and 3 = severe), interstitial mononuclear cell infiltration on a scale of 0–3, 
and cellular crescent formation on a scale of 0–3 according to the percentage of glomeruli 
involved (0 = 0%, 1 = 1–20%, 2 = 21–50%, and 3 =   1  50%). The sum of these numbers was 
the AI (maximum = 9). The chronicity index (CI) was obtained by determining the num-
ber of glomeruli demonstrating fibrous crescents and the presence of segmental or global 
sclerosis; each of these factors was scored on a scale of 0–3 according to the percentage of 
glomeruli involved (0 = 0%, 1 = 1–20%, 2 = 21–50%, and 3 =   1  50%). Tubular atrophy and 
interstitial fibrosis were also each scored on a scale of 0–3. The sum of these numbers was 
the CI (maximum = 12). Tubulointerstitial (TI) changes were classified according to TI 
scores described by Foster et al.   [25]  . In brief, the interstitial mononuclear cell infiltration, 
interstitial edema, tubular damage, and interstitial fibrosis/tubular atrophy were each 
scored on a scale of 0–2 on the basis of the percentage of TI lesions involved (absent = 0%, 
1 = 1–50%, and 2 =   1  50%). The second renal biopsies were performed after completion of 
therapy.104
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  Treatment  Protocol 
  The treatment regimen consisted of MPT (30 mg   kg   – 1   day   – 1   i.v., maximum 1,000 mg/
day) for 3 consecutive days each week for 3 weeks, followed by combination therapy of alter-
nate-day oral prednisolone (initially 2 mg/kg, maximum 60 mg) and antiplatelet agents (di-
pyridamole or dilazep hydrochloride 3–5 mg   kg   – 1   day   – 1  ) for 24 months. After 3 months, the 
dosage of alternate-day oral prednisolone was decreased by 1 mg/kg (maximum, 40 mg) and 
gradually tapered off according to the proteinuria grade. Tonsillectomy was performed be-
tween cycles of MPT during oral prednisolone (2 mg   kg   – 1   day   – 1  ) therapy. In addition, 2 
patients (Nos. 7 and 8) whose initial renal biopsy had shown   6  50% crescentic glomeruli 
(ISKDC classification: grade IV) also received intravenous cyclophosphamide therapy (500–
1,000 mg/m  2   once a month; total of 6,000 mg/m  2  ) followed by azathioprine (2–2.5 mg   
kg    – 1   day   – 1  ) after MPT and tonsillectomy.
  S t a t i s t i c s  
  The data are expressed as means   8   SD. They were analyzed using a paired t test with 
StatMate for Windows (GraphPad Software, La Jolla, Calif., USA). The disappearance rates 
of proteinuria and hematuria were analyzed using the Kaplan-Meier method. A value of
p   !   0.05 was considered significant.
  R e s u l t s  
The clinical characteristics of the 9 patients at the first renal biopsy are shown in  table 1 . 
The patient population consisted of 3 boys and 6 girls, with a median age at HSP onset of
7.2   8   2.3 years (range, 4.2–11.3 years). The interval from the onset of HSP to HSPN was
3.0   8   6.0 months (range, 0.2–19 months). The mean period between the onset of HSPN and 
initiation of therapy was 3.0   8   3.8 months (range, 0.7–13 months). The mean interval from 
the first biopsy to the second biopsy was 20.8   8   5.5 months. All of the patients had heavy 
proteinuria with hematuria (patient 5 had macrohematuria). One patient (No. 7) had ne-
phrotic syndrome. No patients had renal insufficiency (eGFR   !  60 ml/min/1.73 m  2  ) or hy-
pertension. The mean u-TP/Cr, serum albumin, serum IgA, and eGFR were 5.0  8  5.6 g/g Cr, 
3.3   8   0.6 g/dl, 154.7   8   77.8 mg/dl, and 110.4   8   12.4 ml/min/1.73 m  2  , respectively. Clinical 
status was grade 2 for 8 patients and grade 4 for 1 patient. The grades of glomerular changes 
according to the ISKDC classification at the initial biopsy were grade IIb for 1 patient, grade 
IIIa for 3 patients, grade IIIb for 3 patients, and grade IVb for 2 patients. The mean AI, CI, 
and TI scores were 4.0   8   0.7, 1.7   8   1.3, and 1.3   8   0.7, respectively. All patients completed 
the study. All of the patients’ tonsils showed chronic tonsillitis on histological results.
 At the second renal biopsy, 6 patients had normal urinalysis and renal function (state A), 
2 patients (Nos. 2 and 6) had minor urinary abnormalities (state B), and 1 patient (No. 8) had 
active renal disease (state C). Serum albumin had significantly increased (4.3   8   0.2 g/dl,
p  !  0.01), and the serum IgA, AI , and TI scores had significantly decreased (88.1  8  30.8 mg/
dl, p   !   0.05; 2.0   8   1.2, p   !   0.01, and 0.4   8   0.5, p   !   0.01, respectively). CI and eGFR values 
did not change compared with those at the first renal biopsy (  table 2  ). All of the patients but 
1 (No. 6) had an improved ISKDC grade. Two patients (Nos. 6 and 8) received additional 
therapy because they exhibited persistent proteinuria and hematuria at the second renal bi-
opsy, although proteinuria and hematuria largely decreased. Patient No. 6 had mild protein-
uria (u-TP/Cr of approximately   1  0.3–0.4 g/g Cr) and hematuria that persisted at the second 
renal biopsy, so the patient received 2 cycles of MPT followed by azathioprine and an angio-
tensin-converting enzyme inhibitor (ACEI; enalapril). Patient 8 received azathioprine com-
bined with alternate-day oral prednisolone; however, heavy proteinuria (u-TP/Cr of approx-105
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imately   1  1–2 g/g Cr) and hematuria persisted at the second renal biopsy. Therefore, he re-
ceived 3 cycles of MPT followed by mizoribine (5 mg   kg   – 1   day   – 1  ) and an ACEI (enalapril). 
Two patients received an ACEI to decrease proteinuria and for renal protection, but not for 
hypertension.
  The median follow-up lasted 43.6  8  8.2 months (range, 31.0–53.0 months). At the most 
recent follow-up, 8 patients were in state A and only 1 (No. 8) was in state B. Two patients 
(Nos. 6 and 8) had received an ACEI at this point in time. All of the patients had negative 
hematuria within 38 months, and the mean time for hematuria disappearance was 16.1   8  
13.1 months (range, 1–38 months). All but 1 patient (No. 8) had negative proteinuria within 
Table 1.   Histopathological and laboratory data of all patients
Pa-
tient
No.
Sex Age at 
biopsy
years
u-TP/Cr 
g/g Cr
Interval 
between 
biopsies 
months
AI CI TI ISKDC 
grade
Albu-
min 
g/dl
eGFR 
ml/min/
1.73 m2
Follow-up 
months
1F 9.2 6.4 24 4
1
2
0
1
1
IIIb
I
2.6
4.6
104.5
103.7
53
2M 6.8 1.1 24 4
2
1
2
1
1
IIIa
IIIa
3.7
4.2
122.6
121.7
51
3F 9.7 1.9 25 4
2
1
1
2
1
IIIb
IIIa
4.0
4.4
128.6
117.9
46
4F 5.8 1.5 10 3
1
0
1
1
1
IIIa
IIIa
3.8
4.3
98.7
111.5
49
5F 7.3 5.3 23.5 4
2
2
1
1
0
IIIb
IIIa
3.0
4.1
122.6
103.6
49
6 F 11.4 4.2 21 4
4
3
4
1
0
IIIa
IIIb
3.3
4.0
113.6
120.8
35
7M 6.3 19.2 22 5
1
2
2
1
0
IVb
IIIa
2.3
4.4
110.9
112.0
44
8M 5.3 3.2 13 5
4
4
2
3
0
IVb
IIIa
3.3
4.1
95.8
112.4
31
9F 7.4 2.4 24.5 3
1
0
0
1
0
IIb
IIa
3.5
4.4
96.0
81.2
34
Table 2.   Comparison between the laboratory and histopathological data
Variable First renal biopsy Second renal biopsy Latest follow-up
Serum albumin, g/dl 3.380.6 4.380.2a 4.480.2a
eGFR, ml/min/1.73 m2 110.4812.4 109.4812.4NS 116.0813.0NS
Serum IgA, mg/dl 135.6856.5 88.1830.8b 98.8847.0b
AI 4.080.7 2.081.2a
CI 1.781.3 1.481.2NS
TI scores 1.380.7 0.480.5a
a  p < 0.01, b p < 0.05, vs. first renal biopsy. NS = Nonsignificant. Data are expressed as means 8 SD.106
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24 months, and the mean time for proteinuria disappearance was 6.7   8   7.4 months (range, 
2–24 months;   fig. 1  ). In 7 patients (Nos. 1–5, 7 and 9), proteinuria promptly disappeared 
within 8 months. These patients did not require additional therapy, and there was no asso-
ciation between their first histopathological findings (ISKDC classification and the AI) and 
urine protein quantity. Patient 7 had persistent low-grade proteinuria and hematuria at the 
second biopsy (21 months after the start of therapy). However, after the additional therapy, 
proteinuria promptly disappeared 2 months later. Patient 8 had persistent proteinuria with 
a u-TP/Cr of approximately 0.5–0.7 g/g Cr without hematuria (clinical status, state B) de-
spite additional aggressive immunosuppressive treatment. Hematuria disappeared in all 
patients, but no association was found between the duration of disappearance and any oth-
er parameter. Furthermore, no decrease in renal function (eGFR in all patients was  1 80 ml/
min/1.73 m  2  ) was noted, and persistent low levels of serum IgA (98.8   8   47.0 mg/dl) were 
noted. None of the patients progressed to state D during the course of the study, and none 
experienced recurrence and/or exacerbation of HSPN or a relapse of HSP after treatment 
initiation. 
    No serious complications were reported during the course of therapy, and all complica-
tions were reversible. No patients developed glaucoma, cataract, diabetes, or hypertension. 
No major or minor infections were observed. Four patients had body weight gain   1 10%  of 
the standard weight for their age at the time of the second renal biopsy. The growth rate did 
not change significantly during the prednisolone therapy, and no patients showed a stature 
of   !  –2.0 SD for their age. Dual-energy X-ray absorption results were not significantly differ-
ent before and after the treatment. No patients required a change in the therapy regimen due 
to side effects. 
  Discussion 
 Although previous reports have indicated that the prognosis for most pediatric HSPN is 
favorable, patients with   1  50% crescents, nephrotic syndrome, hypertension, or renal insuf-
ficiency at onset have been reported to be at risk of a poor outcome   [1–6]  . In addition, mor-
bidity among HSPN patients with persistent heavy proteinuria is high, and the decision to 
treat HSPN should be based on clinical presentation rather than on biopsy findings alone  [7] . 
The limitations associated with predicting the future prognosis according to clinical features 
or histological evaluation at early-stage HSPN may provide us with a rationale for treating 
  Fig. 1.   The times for disappear-
ance of proteinuria (u-TP/Cr 
  !  0.2 g/g Cr) and hematuria are 
shown. 107
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all proteinuric HSPN children   [26]  . In addition, it was recently reported that patients with 
ISKDC grade I–III and serum albumin   1  2.5 g/dl might have recovered with ACEI and/or 
angiotensin receptor blockers   [27]  . 
    From the results of such reports, we concluded that, with no definite criteria about the 
treatment decisions in HSPN patients, the treatment must be judged on the basis of the clin-
ical features, histopathology, and laboratory findings. In the present study, all but 2 of our 
HSPN patients had serum albumin  1 2.5 g/dl and/or ISKDC grade II or III. It is controversial 
whether such HSPN patients need aggressive therapy. In general, however, early treatment is 
necessary for severe HSPN patients, and it is widely recognized that HSPN patients with 
heavy proteinuria and/or  1  50% crescents pathologically have a poor renal prognosis. We se-
lected HSPN patients with heavy proteinuria for treatment adaptation and then determined 
the treatment intensity (intravenous cyclophosphamide therapy followed by azathioprine) by 
the severity of pathology. Thus, we decided that all patients in the present study would receive 
the aggressive treatment.
    Several previous studies have reported improvement in renal symptoms in pediatric 
HSPN patients treated with immunosuppressive agents, including MPT alone  [28] , MPT and 
urokinase pulse therapy   [29]  , oral cyclophosphamide   [30]  , corticosteroids in combination 
with cyclophosphamide  [31, 32] , cyclosporin A  [33] , azathioprine with steroids  [34] , and plas-
mapheresis   [35]  . However, the severity of the cases in these studies differed, and there is no 
clear consensus as to which patients with HSPN should be treated or what therapeutic regi-
men should be used. No treatment regimen has been evaluated in randomized, controlled 
trials because of the small number of HSPN patients and the variable severity of HSPN. 
  Recently, case reports were published on the efficacy of tonsillectomy for HSPN in adults 
and children  [15, 17] . Persistent proteinuria and chronic progressive renal dysfunction should 
be considered therapeutic targets in HSPN, and tonsillectomy combined with subsequent 
pulse steroids may be a therapeutic strategy deserving consideration for patients with those 
conditions. Furthermore, the efficacy of tonsillectomy plus MPT was reported for severe pe-
diatric HSPN in a retrospective study. It was concluded that tonsillectomy in combination 
with steroid therapy was able to induce complete remission of various grades of HSPN; ton-
sillectomy in early-stage HSPN significantly reduced the time until the urine findings re-
turned to normal, and tonsillectomy appeared to contribute to the prevention of HSPN re-
lapses   [16]  . The 100% success rate of that study in achieving complete remission with HSPN 
therapy could be attributed to prompt intervention against disease activity by steroid admin-
istration, including MPT. Inoue et al.   [36]   also reported that tonsillectomy alone might be 
able to prevent complications of HSPN, thereby contributing to early recovery from HSP in 
children. 
    In blood, subtype IgA1 accounts for 90% of IgA, and approximately 80–90% of IgA1 is 
produced in the tonsils and nasal cavity. In the mechanism of action for HSPN treatment 
with MPT combined with tonsillectomy, production of the IgA1 antibody in the tonsils is 
inhibited because the focal infection is removed by tonsillectomy, as in IgA nephropathy, and 
inferred inflammation in the glomerulus, especially the glomerular capillary, is treated with 
MPT followed by oral prednisolone therapy. A recent report suggested the rationale for the 
superiority of tonsillectomy plus MPT over MPT alone for the treatment of IgA nephropathy: 
tonsillectomy may have effects upstream of the pathogenic mechanism by eliminating anti-
genic stimuli from the tonsillar mucosa, and MPT can influence the area downstream of the 
pathogenic mechanism by suppressing the abnormal immune response in the bone marrow 
that leads to subsequent inflammation in the renal glomeruli   [37]  . A similar mechanism is 
possible for the effect of MPT plus tonsillectomy on HSPN. Our study showed that the serum 
IgA level decreased significantly after tonsillectomy, a low level of serum IgA persisted for 
an extended period, and proteinuria promptly disappeared in all but 1 patient. These find-108
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ings suggest that a reduction in polymeric IgA1 production did not lead to the development 
of inflammation in the glomeruli and eliminated antigenic stimuli from the tonsillar mu-
cosa by decreasing the serum IgA1 level; this led to clinical improvement in all patients.
    Niaudet and Habib   [28]   conducted a prospective study of the treatment of severe forms 
of childhood HSPN and evaluated the effects of MPT therapy alone on the outcome and pa-
thology of nephropathy. They reported that 11 of 38 children (21%) still exhibited nephropa-
thy, 4 had persistent nephropathy, and 4 progressed to end-stage renal failure. Moreover, a 
repeat biopsy within an interval of 7–24 months showed deterioration in the CI, despite an 
improvement in the AI in both the clinical recovery group and the group with minimal uri-
nary abnormalities. In contrast, in our study, all but 1 patient showed negative proteinuria 
within 43 months of observation without any deterioration in renal function. Moreover, in 
addition to the decrease in AI, CI remained unchanged at the mean follow-up time of 20.8 
  8  5.5 months. The HSPN patients in the study by Niaudet and Habib  [28]  had higher disease 
severity than did the patients in our study, and the treatment protocol was different with re-
gard to the number of MPT treatments and the therapy period. Although we cannot compare 
the 2 studies easily, our results suggest that the addition of tonsillectomy to MPT contrib-
uted beneficial effects. 
  Furthermore, the importance and efficacy of a prompt treatment initiation for achieving 
complete remission in patients with severe proteinuric HSPN has been demonstrated by sev-
eral authors. Tanaka et al.  [32]  treated 9 patients with nephrotic-range HSPN with predniso-
lone and cyclophosphamide no later than 4 weeks after the onset of HSPN, and 7 of these 
patients achieved complete remission. In addition, plasmapheresis has been reported to sig-
nificantly improve the renal outcome of severe pediatric HSPN if it is performed within
4 weeks of the onset of HSPN   [35, 38]  . When the start of plasmapheresis was delayed to
  1  8 weeks after the onset of HSPN, the patients inevitably developed end-stage renal failure 
 [35, 39] . All of these reports suggest that early suppression of disease activity by immunosup-
pressants or elimination of circulating immune complexes is essential for attaining clinical 
remission of HSPN. However, even after such aggressive and prompt therapeutic approaches, 
a subset of HSPN patients does not respond well and may progress to end-stage renal failure 
through successive flare-ups. Indeed, in our study, 1 patient (No. 8) still had low-grade pro-
teinuria even after additional treatments with MPT and immunosuppressants. However, all 
patients began treatment soon after the renal biopsy and promptly experienced a reduction 
in proteinuria and hematuria (8 patients achieved complete remission). Accordingly, early 
diagnosis based on renal biopsy and prompt initiation of immunosuppressive treatment may 
contribute to a favorable outcome   [25, 31]  .
    Because it was thought that the patients with ISKDC grade IV (Nos. 7 and 8) had a poor 
prognosis, aggressive treatment was required. Many studies have considered the prognostic 
significance of glomerular crescents in renal biopsies, and most reports agree that the pres-
ence of   1  50% crescents at onset indicates a poor prognosis   [4, 8, 19, 28]  . Therefore, we used 
an intravenous cyclophosphamide therapy regimen as an additional treatment. Cyclophos-
phamide is a powerful immunosuppressive drug, and its efficacy through oral administra-
tion in pediatric HSPN cases has been reported   [30]  . For adult cases, intravenous cyclophos-
phamide therapy (1,000 mg/m  2  once a month for 6 months) has been reported to be effective 
 [40] . However, this therapy is very strong, so we may have overestimated the efficacy of MPT 
combined with tonsillectomy. 
    In conclusion, our study was the first prospective study of children with heavy protein-
uric HSPN receiving early treatment of MPT combined with tonsillectomy, regardless of the 
episode of macrohematuria at tonsillitis and severity of histopathological findings. Our re-
sults were excellent compared with those of previous studies and suggest that MPT com-
bined with tonsillectomy is effective for heavy proteinuric HSPN in children and may ame-109
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liorate its histopathological progression and improve the clinical outcome. However, because 
the severity of proteinuria is the main risk factor for the progression of glomerular disease 
  [41]  , additional observations, particularly long-term studies, are necessary to evaluate long-
term efficacy. To date, no information is available on the clinical efficacy of tonsillectomy on 
the long-term renal survival of patients with HSPN compared with patients with IgA ne-
phropathy   [12, 13]  . In addition, there are some limitations to this study – namely, the small 
number of patients and the lack of a control group. For more accurate information, further 
evaluation will be required to validate our results. Despite these limitations, the present study 
suggests that early treatment with MPT combined with tonsillectomy is beneficial for chil-
dren with a clinically severe form of HSPN.
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